Imagine stepping on a scale that doesn’t just tell you your weight but predicts how long you might live. Sounds like science fiction, right? Well, Withings is turning this into reality with its latest innovation, the Body Scan 2, a smart scale they’re boldly calling a ‘longevity station.’ But here’s where it gets controversial: can a scale really become your personal health oracle? Let’s dive in.
At CES 2026, Withings unveiled the $599.95 Body Scan 2, a device that takes smart scales to a whole new level. Unlike traditional scales that focus solely on weight, this one zeroes in on cardiovascular and metabolic health. How? By packing eight electrodes on the scale itself and four more in a retractable handle. This design isn’t entirely new—it’s an evolution of the original Body Scan—but the handle is a game-changer. Most smart scales rely only on foot electrodes, using lower-body data to estimate overall health. Withings’ approach, however, incorporates upper-body data, making it far more accurate. And this is the part most people miss: by combining both, the Body Scan 2 offers a more holistic view of your body composition.
But the real star of the show is its 90-second ‘longevity assessment.’ This isn’t just a fancy term—it analyzes over 60 biomarkers across five key categories: heart performance, hypertension risk, artery health, cellular health, and glycemic regulation. Antoine Joussain, Withings’ director of product management, explains, ‘We’re building a vision where powerful biomarkers are measured daily, right when you step on the scale.’ Sounds impressive, but tracking 60 metrics can be overwhelming. That’s why Withings simplifies it with a Health Trajectory score, which visualizes your healthspan—essentially, how many healthy years you have ahead. Joussain adds, ‘We keep it simple with clear indicators you can follow daily, weekly, or monthly. The rest? We’ll interpret for you.’
Now, this isn’t entirely uncharted territory. Companies like Whoop and Oura have already dipped their toes into similar waters, offering scores that estimate aging based on cardiovascular, sleep, and activity data. But Withings’ twist is its noninvasive approach to metabolic health. Instead of blood tests, the Body Scan 2 uses bioimpedance spectroscopy (BIS) and—wait for it—foot sweat. Yes, foot sweat. By stimulating sweat glands with a tiny current, the scale gauges their health. ‘If the activity is high, your glands are healthy,’ Joussain explains. This method, along with BIS, provides frequent, easy-to-obtain insights into metabolic health, though they’re not meant for diagnosis—think of them as early warning signs.
The convenience of a smart scale is undeniable. It’s a device many already use daily, making it the perfect tool for long-term health tracking. But there’s a catch. Scales can be emotionally charged, triggering body dysmorphia or disordered eating for some. Withings acknowledges this with an Eyes-Closed Mode, where measurements are replaced with emojis on the scale but still recorded in the app. The goal? To redefine the scale as a tool for overall health, not just weight.
However, the road isn’t without bumps. Regulatory hurdles loom large, with features like hypertension risk notifications and EKG readings requiring FDA clearance. Withings’ track record with the FDA is mixed—its ScanWatch took nearly two years to clear, while the U-Scan urinalysis lab bypassed clearance altogether. Joussain remains optimistic, though, hinting at a ‘new kind of certification’ to expedite approvals without compromising research. If all goes well, the Body Scan 2 will hit shelves in Q2 2026, complete with GDPR, HIPAA, and ISO privacy certifications.
So, is the Body Scan 2 the future of personal health monitoring, or just another gadget? And more importantly, are we ready to trust a scale with our longevity? Let us know your thoughts in the comments—this is one debate you won’t want to miss.
